Transcriptional and Posttranscriptional Regulation of Cytokine Gene Expression in HIV-1 Antigen-Specific CD8<sup>+</sup> T Cells That Mediate Virus Inhibition

Tamika L. Payne,<sup>a,b</sup> Jeff Blackinton,<sup>a</sup> Alyse Frisbee,<sup>d</sup> Joy Pickeral,<sup>b</sup> Sheetal Sawant,<sup>d</sup> Nathan A. Vandergrift,<sup>d</sup> Stephanie A. Freel,<sup>b,d</sup> Guido Ferrari,<sup>b,d</sup> Jack D. Keene,<sup>a</sup> Georgia D. Tomaras<sup>a,b,c,d</sup>

Departments of Molecular Genetics and Microbiology,<sup>a</sup> Surgery,<sup>b</sup> and Immunology<sup>c</sup> and Duke Human Vaccine Institute,<sup>d</sup> Duke University, Durham, North Carolina, USA

ABSTRACT

The ability of CD8<sup>+</sup> T cells to effectively limit HIV-1 replication and block HIV-1 acquisition is determined by the capacity to rapidly respond to HIV-1 antigens. Understanding both the functional properties and regulation of an effective CD8<sup>+</sup> response would enable better evaluation of T cell-directed vaccine strategies and may inform the design of new therapies. We assessed the antigen specificity, cytokine signature, and mechanisms that regulate antiviral gene expression in CD8<sup>+</sup> T cells from a cohort of HIV-1-infected virus controllers (VCs) (<5,000 HIV-1 RNA copies/ml and CD4<sup>+</sup> lymphocyte counts of ≥400 cells/μl) capable of soluble inhibition of HIV-1. Gag p24 and Nef CD8<sup>+</sup> T cell-specific soluble virus inhibition was common among the VCs and correlated with substantial increases in the abundance of mRNAs encoding the antiviral cytokines macrophage inflammatory proteins (MIP-1α, MIP-1β, granulocyte-macrophage colony-stimulating factor (GM-CSF); lymphotactin (XCL1); tumor necrosis factor receptor superfamily member 9 (TNFRSF9); and gamma interferon (IFN-γ). The induction of several of these mRNAs was driven through a coordinated response of both increased transcription and stabilization of mRNA, which together accounted for the observed increase in mRNA abundance. This coordinated response allows rapid and robust induction of mRNA messages that can enhance the CD8<sup>+</sup> T cells’ ability to inhibit virus upon antigen encounter.

IMPORTANCE

We show that mRNA stability, in addition to transcription, is key in regulating the direct anti-HIV-1 function of antigen-specific memory CD8<sup>+</sup> T cells. Regulation at the level of RNA helps enable rapid recall of memory CD8<sup>+</sup> T cell effector functions for HIV-1 inhibition. By uncovering and understanding the mechanisms employed by CD8<sup>+</sup> T cell subsets with antigen-specific anti-HIV-1 activity, we can identify new strategies for comprehensive identification of other important antiviral genes. This will, in turn, enhance our ability to inhibit virus replication by informing both cure strategies and HIV-1 vaccine designs that aim to reduce transmission and can aid in blocking HIV-1 acquisition.
University Medical Center, and had presumed clade B infections (due to AIDS, NIAID, NIH [HIV-1 PTE peptides]) (33) represent the following.

Viral loads and CD4 counts are measured values for samples used in experiments. Virus controllers were recruited from the Adult Infectious Diseases Clinic, Duke University Medical Center, and had presumed clade B infections (due to the geographical location).

MATERIALS AND METHODS

Patient cohorts. Eleven antiretroviral therapy (ART)-naive HIV-1-infected virus controllers (Table 1) (maintaining plasma HIV-1 loads of <5,000 RNA copies/ml and CD4+ lymphocyte counts of >400 cells/μl) and one ART-experienced individual (VC15) enrolled through the Infectious Diseases Clinic at the Duke University Medical Center and with CD8+ T-cell-mediated virus inhibition were studied here. VC15 was previously on ART but naturally controlled his/her viremia (maintaining a VL of <5,000 copies/ml and a CD4 count of >800 cells/μl) for two years posttherapy before being enrolled in our study. While in the study, VC15 had VLs of 1,590 to 2,950 copies/ml and CD4 counts of 721 to 801 cells/μl. VC27 maintained VLs of <100 to 2,690 copies/ml with the exception of two draw dates on which his/her VLs were 5,190 and 5,360 copies/ml.

Notably, the RNA was DNase (Ambion) treated after initial RNA extraction, and CD4 and CD8+ T cells. After 48 h, the TZM-bl cells were lysed and the firefly luciferase content of the lysate was measured. Virus inhibition was calculated as the log reduction in relative light units (RLU) (luciferase) of wells with CD8+ T cells compared to control wells without CD8+ T cell effectors. The cutoff for significant virus inhibition (>0.39-log-unit reduction) was determined using seroreactive control subjects.

Multiparameter intracellular-cytokine-staining assay. Flow cytometric analyses of HIV-1-specific CD8+ T cells were performed as previously described (5, 6, 17). Briefly, peripheral blood mononuclear cells (PBMCs) were stimulated with the PTE peptide pools as described above for 5.5 h. Stimulation with 0.2 μg/ml staphylococcal enterotoxin B, also for 5.5 h, was used as a positive control. The titer of each antibody was determined to obtain the saturating concentration used for the final staining. Stimulations were conducted in the presence of 0.5 μg/ml anti-CD107a phycoerythrin (PE)-Cy5 (clone HA43; BioLegend), 5 μg/ml brefeldin A (Sigma), and 4 μl/6 ml Golgi Stop (BD Pharmingen) for 5.5 h at 37°C in 5% CO2. After washing, the cells were stained with a viability indicator (LIVE/DEAD Fixable Aqua Dead Cell Stain Kit; Molecular Probes) in phosphate-buffered saline for 20 min at room temperature. The cells were then washed and stained for 20 min at 4°C with a surface stain cocktail containing anti-CD3–APC-H7 (clone SK7; BD Biosciences), anti-CD4–BV605 (clone RPA-T4; BD Horizon), anti-CD8–PacBlue (clone RPA-T8; BD Pharmingen), anti-CD27–Cy7–PE (clone M-T271; BD Pharmingen), anti-CD45RO–ECD (clone UCHL1; Beckman Coulter), and anti-CCR7–Alexa Fluor 700 (clone 150503; BD Pharmingen). The PBMCs were subsequently washed twice and then fixed and permeabilized with fixation/permeabilization solution (BD Cytofix/CytoPerm). The PBMCs were washed twice in Perm/Wash buffer (BD Perm/Wash) diluted 1:10 with distilled water. The cells were then stained with anti-IFN-γ–BV650 (4S.B3; Biologic), anti-interleukin 2 (IL-2)–allophycocyanin (APC) (clone MQ1-17H12; BD Pharmingen), anti-MIP-1α–fluorescein (clone 93342; BD Pharmingen), anti-MIP-1β–PE (clone D121-1351; BD Pharmingen), and anti-TNF-α–peridinin chlorophyll protein (PerCP)–cyanine 5.5 (clone MAb11; eBioscience) for 45 min at 4°C. After washing and fixation, the subsets were stained with custom-made LSRII (BD Bioscience, San Jose, CA) within the next 24 h. Gates were set to include singlet events, lymphocytes, live CD3+ cells, and CD4+ and CD8+ subsets. From the total CD4+ and CD8+ populations. The cutoff was identified as CD45RO–CD27+. This subset was excluded from the subsequent analysis, including only the memory population. Antigen-specific populations were identified within the memory population as single-function cells shown in the sequential single cytokine/chemokine/degranulation gates. Responses were considered positive if the percentage of antigen-specific cells was 3-fold above the memory population. Antigen-specific populations were identified within the memory population as single-function cells shown in the sequential single cytokine/chemokine/degranulation gates. Responses were considered positive if the percentage of antigen-specific cells was 3-fold above the background and greater than 0.05% after background subtraction. Data analysis was performed using FlowJo 9.6.4 software (TreeStar Inc.).

4sU incorporation and PCR analysis. To assess transcription and mRNA decay independently, 4-thiouridine (4sU) (200 μM) was added 1 h prior to harvest of cells (4.5 h after the start of peptide stimulation). Cells were harvested in 1 ml of TRIzol, and RNA was extracted following the manufacturer’s protocols (Life Technologies). Separation of 4sU-labeled RNA from unlabeled RNA was performed using a highly efficient (>90%) biotinylination method as described previously (34) with minor modifications. Notably, the RNA was DNase (Ambion) treated after initial RNA decay, with evidence for potential differences in the regulation of mRNA between Nef- and Gag-specific CD8+ T cells.
amino acid number: Env1 (E1), amino acids 4 to 296 (gp120); Env2 (E2), amino acids 297 to 488 (gp120); Env3 (E3), amino acids 489 to 602 (gp41); Env4 (E4), amino acids 603 to 9516

This method led to calculated variations of RNAs for each sample were reverse transcribed into cDNA using an extraction from cells, and streptavidin MyOne C1 Dynabeads (Invitrogen) were used to extract biotinylated 4sU RNA. Subsequently, three populations of RNAs for each sample were reverse transcribed into cDNA using an iScript kit (Bio-Rad): total RNA (T), labeled RNA (L), and unlabeled RNA (U). Real-time PCR was performed on each population of RNA and then normalized for the relative amount of input RNA. The abundance of mRNA was represented by the measurement of the total RNA sample (T). Net transcription was represented by the labeled fraction of mRNA (L). The decay rate (DR) was calculated from measurements of labeled (L) and unlabeled (U) mRNA, as a function of L/U: ln(1−L/U). An apparent RNA half-life was calculated using the decay rate, −t × ln[2]/DR, where t is the time of 4sU incorporation (1 h for the purposes of these experiments). Two assumptions of this method are that transcription and stability are constant over the period of measurement. These assumptions result in more conservative conclusions regarding changes in stability between samples, especially among short-lived mRNAs. The mRNA stabilities calculated using 4sU-based measurements correlate very well with those calculated using other established methods, such as actinomycin D (34). To compensate for a bias against labeling of short mRNAs, the mRNA stabilities calculated using 4sU-based measurements of measurement. These assumptions result in more conservative conclusions among different patients due to the longer XCL half-life (average, 8.39 h) and the fact that RNA stability calculations are prone to greater error with longer intrinsic mRNA survival.

**Time course prediction modeling.** 4sU labeling was performed at 1-h intervals for 6.5 h after stimulation (see Fig. 7A), resulting in continuous measurement of transcription. The amounts of RNA in each population were measured as described above. Predictions of RNA abundance that assumed a constant decay rate were determined based on a previously developed model (40) that uses the unstimulated RNA abundance and then iteratively adds amounts of transcripted RNA in each hour and subtracts a decay rate dependent on the amount of decayed RNA in that hour: for time i, Ti = Ti−1 + [Ni − Ti−1 × DRi]b, where Ti is the initial measured total, N is the net transcription at time i, and DRi is the initial calculated decay rate. Because several of the mRNAs are short (~1,000 bp) and contain relatively few uridines, we corrected for the stochastic likelihood of failing to include a 4sU in place of a uridine for an entire mRNA, as outlined previously (37). Subsequently, modeling the optimized decay rate solved for the decay rate in the above equation, since the totals are observed: DRi_optimized = (Ti−1 + Ni − Ti−1)/Ti−1.

Data from two biological replicates were independently treated through the modeling and then averaged using fold change measurements in predicted and observed abundances.

**Statistical analyses.** Statistical analyses were performed using Graph-Pad Prism (GraphPad Software) and SAS v9.3 (SAS Institute). Correlations between the cytokine expression level and virus inhibition were calculated using the Spearman’s rank correlation coefficient (GraphPad Software). Appropriate SAS PROC tests were used to calculate raw P values using Wilcoxon exact tests and for controlling the false-discovery rate (FDR) using the Benjamini and Hochberg method (41).

**RESULTS**

**Soluble HIV-1 inhibition from p24- and Nef-specific CD8+ T cells.** We first evaluated the antigen specificity of CD8+ T cells that inhibit HIV-1 via soluble mechanisms by using an HIV-1-specific transwell sVIA (6). Primary CD8+ T cells from VCs were stimulated with Env, Nef, Pol, or Gag HIV-1 p24 peptide (33) pools for 5.5 h and then tested for the ability to inhibit an R5-tropic clade B founder virus, CH040.c (31, 32). In 11 of 12 VC patients (Table 1), antigen-specific stimulation of CD8+ T cells mediated soluble inhibition of HIV-1 replication (Table 2). The most common

**Table 2. Antigen-specific CD8+ T cell inhibition of HIV-1 replication**

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Env1</th>
<th>Env2</th>
<th>Env3</th>
<th>Env4</th>
<th>Gag</th>
<th>Pol</th>
<th>Nef</th>
</tr>
</thead>
<tbody>
<tr>
<td>VC9</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>0.44</td>
<td>0.53</td>
<td>0.45</td>
<td>0.64</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC11</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC15</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC16</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC20</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC23</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC24</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC26</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC27</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC28</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC29</td>
<td>0.51</td>
<td>0.41</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>VC30</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
<td>&lt;0.39</td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>9</td>
<td>1</td>
</tr>
</tbody>
</table>

**TABLE 2.** Antigen-specific CD8+ T cell inhibition of HIV-1 replication. The most common

The log10 reduction values for HIV-1 peptide–specific soluble inhibition by CD8+ T cells from HIV-1 VCs are shown. sVIA was used to measure the inhibitory capacities of antigen-stimulated primary CD8+ T cells from 12 HIV-1+ virus controllers. Virus inhibition was measured as log reduction in CH040.c (transmitted/founder virus) replication without CD8+ T effector cells. Values of >0.39-log-unit reduction in virus replication compared to a no-CD8+ T cell control indicate significant inhibition and are reported (boldface). A value of <0.39 (lightface) indicates a nonsignificant log10 reduction value. The peptide pools were divided as follows to represent HIV-1 regions based on the HXB2 amino acid number: Env1 (E1), amino acids 4 to 296 (gp120); Env2 (E2), amino acids 297 to 488 (gp120); Env3 (E3), amino acids 489 to 602 (gp41); Env4 (E4), amino acids 603 to 840 (gp41); Gag1 (G1), amino acids 1 to 128 (p17); Gag2 (G2), amino acids 131 to 361 (p24); Gag3 (G3), amino acids 362 to 486 (p17); Pol1 (P1), amino acids 1 to 152 (pro tease); Pol2 (P2), amino acids 156 to 447 (p51); Pol3 (P3), amino acids 452 to 709 (p51 plus p15); Pol4 (P4), amino acids 711 to 988 (p31); Nef, amino acids 1 to 193.

**Total number of values of >0.39-log-unit reduction in virus replication compared to a no-CD8+ T cell control.**

...
epitope specificities of cells that mediated soluble virus inhibition were Gag p24 (Gag2) (9 out of 12 VC patients) and Nef (7 out of 12 VC patients). The second most common CD8+ T cell specificities that inhibited virus replication were Gag p17 (Gag1) and protease (Pol1) (4 out of 12 VC patients each).

HIV-1 antigen-specific CD8+ T cells have increased expression of IFN-γ, MIP-1α, MIP-1β, GM-CSF, XCL1, and TNFRSF9 that correlate with virus inhibition. The effector function of CD8+ T cells includes the antiviral activity of cytokines (42–44). In order to identify correlates of antiviral control, we assessed the expression of a panel of cytokines, including MIP-1α, MIP-1αP, MIP-1β, IFN-γ, XCL1, GM-CSF, RANTES, and TNFRSF9. We and others have shown that IFN-γ and the β-chemokines MIP-1α and MIP-1β are associated with CD8+ T cell inhibition of HIV-1 (17, 42, 44–48). MIP-1α, MIP-1αP, and MIP-1β bind CCR5 and block the entry of R5-tropic viruses (including transmitted/founder viruses) in CD4+ T cells including cytokine (TARC) (56) in unstimulated and 5.5-h Gag p24-peptide stimulation and compared the cytokine expression to that of unstimulated autologous cells. Compared to unstimulated cells, p24-stimulated CD8+ T cells had increases in mRNAs for IFN-γ, MIP-1α, MIP-1αP, MIP-1β, TNFRSF9, XCL1, and GM-CSF (Fig. 1A). In contrast, no change was seen in the mRNA expression of RANTES, another β-chemokine with HIV-1-suppressive activity (44).

We next measured the levels of mRNA expression of the aforementioned cytokines and the CXCR4-interacting cytokines macrophage-derived chemokine (MDC) (55) and thymus- and activation-regulated chemokine (TARC) (56) in unstimulated and 5.5-h-stimulated (Gag p24, Nef, or Gag p17) CD8+ T cells from 10 additional VC patients. For the Gag p24 experiments, we divided the patients into two groups: those with p24-specific soluble virus inhibition (VC11, -23, -26, -27, -28, and -29; n = 6) and those without (3 HIV-1-seronegative patients, VC16, and VC24; n = 5) (Table 2). The amounts of mRNA in p24-stimulated CD8+ T cells from VC5 without p24-specific inhibition and seronegative patients were largely unchanged compared to unstimulated cells, p24-stimulated CD8+ T cells compared to unstimulated cells) from patients with Nef-specific inhibition (Table 2). The second most common CD8+ T cell specificities that inhibited virus replication were Gag p17 (Gag1) and protease (Pol1) (4 out of 12 VC patients each).

HIV-1 antigen-specific CD8+ T cells have increased expression of IFN-γ, MIP-1α, MIP-1αP, MIP-1β, GM-CSF, TNFRSF9, and XCL1 mRNAs. (A) Values for fold changes (5.5 h p24 stimulation/unstimulated) in total mRNA abundance (real-time [RT]-PCR) in CD8+ T cells from an HIV-1+ virus controller (VC30). The results are from three independent experiments. The lines represent the median values. (B) Fold changes in total mRNA levels (5.5-h p24-stimulated CD8+ T cells compared to unstimulated cells) from patients with p24-specific inhibition (triangles, n = 6: VC11, -23, -26, -27, -28, and -29) and those without (circles, n = 5: 3 HIV-1-seronegative patients and VC16 and -24). The lines indicate the medians. *, P < 0.05. (C) Values for the fold change in mRNA levels (5.5-h Nef-stimulated CD8+ T cells compared to unstimulated cells) from patients with Nef-specific inhibition (diamonds, n = 4: VC26, -27, -29, and -16) and those without (squares, n = 7: 3 HIV-1-seronegative patients and VC11, -23, -28, and -24). The lines indicate the medians. mRNA abundance was determined via primer-specific PCR. The P values are indicative of significant differences in fold changes in abundance in patients with antigen-specific inhibition compared to those without. The P values were calculated using the Wilcoxon exact test, controlling for false discovery using the Benjamini and Hochberg method.
stimulated CD8+ and GM-CSF was statistically significant in p24- compared to p17-

<table>
<thead>
<tr>
<th>Variable</th>
<th>Gene</th>
<th>Fold change P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Raw</td>
<td>FDR corrected</td>
</tr>
<tr>
<td></td>
<td>Raw</td>
<td>FDR corrected</td>
</tr>
<tr>
<td></td>
<td>Raw</td>
<td>FDR corrected</td>
</tr>
<tr>
<td></td>
<td>Raw</td>
<td>FDR corrected</td>
</tr>
<tr>
<td></td>
<td>Raw</td>
<td>FDR corrected</td>
</tr>
<tr>
<td>Total mRNA</td>
<td>IFN-γ</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td>MIP-1α</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td>MIP-1αp</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td>MIP-1β</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td>GM-CSF</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td>XCL1</td>
<td>0.017 0.054</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td>Net transcription</td>
<td>IFN-γ</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td>MIP-1α</td>
<td>0.052 0.104</td>
</tr>
<tr>
<td></td>
<td>MIP-1αp</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td>MIP-1β</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td>GM-CSF</td>
<td>0.052 0.104</td>
</tr>
<tr>
<td></td>
<td>XCL1</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.008 0.030</td>
</tr>
<tr>
<td>Apparent half-life</td>
<td>IFN-γ</td>
<td>0.017 0.054</td>
</tr>
<tr>
<td></td>
<td>MIP-1α</td>
<td>0.082 0.147</td>
</tr>
<tr>
<td></td>
<td>MIP-1αp</td>
<td>0.004 0.030</td>
</tr>
<tr>
<td></td>
<td>MIP-1β</td>
<td>0.052 0.104</td>
</tr>
<tr>
<td></td>
<td>GM-CSF</td>
<td>0.537 0.609</td>
</tr>
<tr>
<td></td>
<td>XCL1</td>
<td>0.429 0.500</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.315 0.389</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.230 0.312</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.073 0.133</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.315 0.389</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.315 0.389</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.315 0.389</td>
</tr>
</tbody>
</table>

*P values were calculated using the Wilcoxon exact test to compare fold changes for Gag p24- and Nef-stimulated cells for patients with and without antigen-specific inhibition. Two P values are reported: the raw P value, which is not corrected for multiple comparisons, and the FDR-corrected P value, which controls for the false-discovery rate. The FDR-corrected P values were calculated using the Benjamini and Hochberg method [41]. Boldface indicates significance (P < 0.05), and lightface indicates nonsignificance (P > 0.05).
MIP-1β, GM-CSF, TNFRSF9, and XCL1 mRNAs in CD8+ T cells with p24- and Nef-specific inhibition of HIV-1, we performed 4sU analysis after antigen stimulation (34). 4sU analysis uses incorporation of 4sU into nascent RNAs to physically isolate mRNAs synthesized before 4sU addition from those synthesized after 4sU addition. For a fixed period of 4sU incorporation, comparing 4sU-labeled mRNA across samples allows the calculation of net transcription (total transcription minus the amount of 4sU-labeled RNA that decays prior to cell harvest) while using the ratio of labeled to unlabeled mRNA to infer a decay rate (34). The method has been employed extensively to simultaneously measure mRNA transcription and decay across a variety of systems (34, 40, 57, 58) with greater reproducibility than using actinomycin D (34). We added 4sU to cells 4.5 h after the start of antigen stimulation and then allowed 4sU incorporation for 1 h before lysing the cells and harvesting RNA. In triplicate experiments in CD8+ T cells from patient VC30, we observed highly reproducible increases in the net transcription of several cytokines in p24-stimulated compared to autologous unstimulated cells (Fig. 3A). Notably, however, the change in net transcription was consistently less than the change we observed in total mRNA abundance. This trend was apparent in the other VCs with p24-specific inhibition: in a majority of the cases in which there was a significant increase in gene expression (compared to patients without antigen-specific inhibition).
(Fig. 3C). In patients without antigen-specific virus inhibition, we observed no changes in net transcription. Comparison to Gag p17-stimulated cells (data not shown) mirrored comparison to unstimulated autologous cells. The notable difference between changes in total mRNA and net mRNA transcription (Fig. 4A and B) indicated the potential for the contribution of additional regulatory mechanisms to the control of gene expression. Though there are several possibilities for the other mechanism(s) involved, including the temporal dynamics of transcription, one logical explanation is stabilization of the mRNA itself.

**mRNAs encoding IFN-γ, MIP-1α, MIP-1αP, and MIP-1β are stabilized after stimulation, contributing to the observed increase of RNA expression.** The observed expression of mRNA is the balance between synthesis of new mRNA (transcription) and degradation (decay) of mRNA over time (59). To investigate the role of decay, we used the ratio of 4sU-labeled mRNA to unlabeled mRNA to calculate mRNA decay rates for the selected panel of antiviral cytokines in CD8⁺ T cells. Using these decay rates, we calculated an apparent half-life, the instantaneous measure of the predicted half-life given the cellular conditions, of each message with and without antigen stimulation. For messages from unstimulated cells from VCs and seronegative patients, these apparent half-lives were consistent across the patients tested (Fig. 5A). For example, in the 12 VCs and 2 HIV-1-seronegative subjects examined, the average apparent half-life of the IFN-γ mRNA was 0.63 ± 0.039 h (Fig. 5A), similar to previously published values for the stability of IFN-γ mRNA (60–62). We next calculated the decay rates from VC30 CD8⁺ T cells without stimulation and from autologous cells 4.5 to 5.5 h after stimulation with Gag p24 (Fig. 5B). We observed a consistent increase in the apparent half-life after stimulation with Gag p24 for IFN-γ, MIP-1α, MIP-1αP, MIP-1β, and GM-CSF. We extended this analysis to additional virus controller patients and HIV-1-seronegative individuals. After stimulation, cells from VCs without an antigen-specific antiviral CD8⁺ T cell response had mRNA half-lives that remained highly consistent with those in unstimulated cells. Cells with a p24-specific response showed increases in stability, with MIP-1αP showing the only statistically significant increase (Fig. 5C) (P < 0.05; Wilcoxon exact test, controlling for the FDR [41]). While changes in the apparent half-life in Nef-stimulated (compared to unstimulated) cells did not reach significance when comparing patients with Nef-specific inhibition to those without and correcting for multiple comparisons, the values for IFN-γ and MIP-1β did reach significance when they were not adjusted for comparisons (Fig. 5D and Table 3). In addition, compared to Gag p17-stimulated cells, the increases in stability observed in Nef-stimulated CD8⁺ T cells were significant for IFN-γ, MIP-1α, and MIP-1αP (Table 3). Taken together, the sum of the change in net transcription and the change in mRNA stability corresponded to the differences in the mRNA abundances after antigen stimulation (Fig. 5E and F).

**Virus inhibition correlates with changes in total RNA, transcription, and half-life.** Since the changes in RNA abundance, net transcription, and apparent mRNA half-life were distinct in patients with and without antigen-specific inhibition, we next determined if these measurements correlated with antigen-specific vi-
We examined whether changes in total RNA abundance, transcription, and half-life correlated with the ability of CD8+ T cells to inhibit HIV-1 replication through soluble mechanisms (Fig. 6). Among the seven cytokines tested, the fold changes in the total mRNA abundances of MIP-1α (r = 0.6656; P = 0.026), MIP-1αP (r = 0.7198; P = 0.0125), MIP-1β (r = 0.6273; P = 0.0388), and XCL1 (r = 0.6636; P = 0.26) strongly correlated with soluble inhibition of p24-stimulated cells that have HIV-1-inhibitory activity (Fig. 6A, top row). Change in the net transcription of the mRNAs encoding MIP-1αP (r = 0.6727; P = 0.0233), MIP-1β (r = 0.700; P = 0.0165), XCL1 (r = 0.6273; P = 0.0388), and TNFRSF9 (r = 0.6091; P = 0.0467) also significantly correlated with soluble inhibition by p24-stimulated CD8+ T cells (Fig. 6A, bottom row). In Nef-stimulated CD8+ T cells, the abundance of TNFRSF9 (r = 0.6364; P = 0.0353), net transcription of IFN-γ (r = 0.6182; P = 0.0426), and mRNA half-life of MIP-1α (r = 0.7364; P = 0.0098) significantly correlated with CD8+ virus inhibition (Fig. 6B). RANTES was included as a negative control, and as expected, no correlations were observed (Fig. 6A and B).

**Temporal dynamics of CD8+ T cell responses.** Measuring mRNA stability at fixed times after stimulation allowed us to observe differences in the apparent half-life in the immediately preceding hour. However, the possibility remained that transcription rate dynamics occurring before the addition of 4sU at 4.5 h could explain the observed differences in the apparent half-life. To independently observe the impacts of transcription and stability on total mRNA abundance, we performed 4sU analysis on p24-stimulated CD8+ T cells from VC20 every hour for a full 6.5-hour time course to capture all net transcription (Fig. 7A). From this, we quantified the total mRNA abundance and net transcription at each hour (starting at 0.5 h) after stimulation. Using the decay rate of unstimulated cells (Fig. 5A) and the initial abundance and net transcription for every hour, we predicted the mRNA abundance at each time point, assuming no change in mRNA stability and compared to the measured total (Fig. 7). In cases where mRNA abundances are constant or derive primarily from transcriptional variation, this model is highly accurate (40). Two controls confirmed the accuracy of the model for both stable (RANTES) and a known transcriptionally driven (TNFRSF9) message (Fig. 7C). Substantial deviations from the predictions given by the model suggest that RNA stability is the likely variable. If the observed totals are greater than predicted, it suggests the RNA is stabilized, while if they are less than predicted, it suggests the RNA is destabilized. As shown in Fig. 7D to F, the predicted levels of RNA for MIP-1α, MIP-1β, and IFN-γ were substantially less than the RNA abundances that were observed, suggesting that the RNA is stabilized. For example, the predicted levels of IFN-γ and MIP-1β were approximately half the observed values (Fig. 7D and F), while the observed abundance of MIP-1α was ~25% higher than the model predicted (Fig. 7E). These results suggest that substantial stabilization of the target mRNAs took place in these cells. We further incorporated the variance in stability we observed across VCs, predicting abundances using apparent half-lives that represented the extremes of the observed unstabilized stabilities in the VCs (Fig. 5A). These extreme values still could not mimic the observed results.

We subsequently allowed stability to vary and solved the equation for the optimized mRNA stability for the observed total mRNA abundances. While RANTES and TNFRSF9 minimally change in mRNA stability (Fig. 7G and H), IFN-γ, MIP-1α, and MIP-1β robustly increased in stability, in coordination with the induction of transcription (Fig. 7I to K). Most messages followed a peaked response, where stability was highest during the time of greatest transcription, resulting in maximal increases in mRNA abundance (Fig. 7G to K).

**DISCUSSION**

We report here that a cohort of virus controllers have substantial antigen-specific Gag p24 and Nef CD8+ T cell-mediated antiviral responses that, through soluble mechanisms, inhibit viral replication. Strongly associated with this antigen-specific antiviral activity are increases in mRNA abundances of IFN-γ, MIP-1α, MIP-1αP, MIP-1β, GM-CSF, TNFRSF9, and XCL1. Several of these cytokines, such as the β-chemokines (MIP-1α, MIP-1αP, and MIP-1β) and XCL1 could play pivotal roles in the ability of CD8+ T cells to inhibit virus at entry. Through 4sU RNA analysis, we report the novel observation that the expression of these cytokines

**FIG 4** Measured changes in the transcription rate do not match observed changes in mRNA abundance. Boxes indicate the median as well as the upper and lower quartiles, with whiskers being minimum and maximum values. Lines at y = 1 indicate no change in value (compared to that for unstimulated). The change in total mRNA abundance (green) from Gag p24-stimulated (A) and Nef-stimulated (B) CD8+ T cells from VCs with antiviral activity does not match the change in net transcription (blue) for MIP-1α, MIP-1αP, MIP-1β, IFN-γ, and GM-CSF. For each of these messages, increases in total mRNA for these markers were 1.3- to 3-fold more than the net transcription. In comparison, total mRNA levels from an mRNA that is known to be transcriptionally induced, TNFRSF9, increased similarly to net transcription. The same is true for XCL-1. This indicates that other mechanisms of regulation may play a role in induction of MIP-1α, MIP-1αP, MIP-1β, IFN-γ, and GM-CSF.
FIG 5 Increases in RNA stability of IFN-γ, MIP1α, MIP1α-AP, MIP1β, and GM-CSF contribute to the observed increase in RNA expression. (A) Calculated apparent half-lives are consistent across unstimulated cells from patient cohorts. Apparent half-lives were calculated for the unstimulated CD8⁺ T cells from 12 VCs and 3 seronegative samples. The lines represent the mean values, while the error bars represent standard errors of the mean. (B) Raw GAPDH-normalized apparent half-life values for unstimulated and 5.5-h p24-stimulated CD8⁺ T cells from VC30. The results are from three independent experiments. The lines represent the median values. (C) Values for the fold change in apparent half-life of p24-stimulated CD8⁺ T cells compared to unstimulated cells from patients with 5.5-h p24-specific inhibition (triangles, n = 6: VC11, -23, -26, -27, -28, and -29) and those without (circles, n = 5: 3 HIV-1-seronegative patients and VC16 and -24). The lines indicate the medians. (D) Values for the fold change in apparent half-life of 5.5-h Nef-stimulated CD8⁺ T cells compared to unstimulated cells from patients with Nef-specific inhibition (diamonds, n = 4: VC26, -27, -29, and -16) and those without (squares, n = 7: 3 HIV-1-seronegative patients and VC11, -23, -28, and -24). The lines indicate the medians. The P values are indicative of significant difference in fold changes in apparent half-life in patients with antigen-specific inhibition compared to those without. The P values were calculated using the Wilcoxon exact test, controlling for false discovery using the Benjamini and Hochberg method. (E and F) The sum of changes in transcription and stability fully accounts for observed changes in mRNA abundance in Gag p24 and Nef. Boxes indicate the median as well as the upper and lower quartiles, with whiskers being minimum and maximum values. Lines at y = 1 indicate no change in value (compared to that for unstimulated). The observed total mRNA abundance across VCs, the predicted mRNA abundances based on the observed transcription rates only, the predicted mRNA abundances based on the measured apparent half-lives (stability) only, and the predicted mRNA abundances based on calculations that included observed net transcription and apparent half-life values are shown. All values were normalized to the observed total mRNA abundance of GAPDH of each message.
is controlled at the level of RNA abundance through coordinated regulation of both transcription and mRNA stability, enabling a rapid and robust antiviral response.

Our findings that Gag p24- and Nef-specific CD8\(^+\) T cells are most associated with HIV-1 inhibition agree with previous research (63–67). We previously demonstrated that Gag- and Nef-dominant soluble activity mediated by CD8\(^+\) T cells during acute HIV-1 infection corresponded to the breadth of virus inhibition, as well as immune pressure against transmitted founder viruses, but that this activity was diminished by 6 months postinfection in the patients examined (6). Others have also reported early Gag and Nef CD8\(^+\) T cell antiviral activity in acute infection (68, 69).

In addition, MIP-1\(\beta\), which correlated with inhibition in this study, correlated with initial antiviral responses in acute HIV-1 infection (5). The observation of the similarity of soluble responses in acute patients and VCs suggests that the soluble antiviral activity of CD8\(^+\) T cells that broadly develop during acute infection may be maintained in virus controller patients. This evidence complements an earlier report that long-term nonprogressors maintain functional cytotoxic CD8\(^+\) T cells that are lost in progressors (70) and indicates that further longitudinal studies to investigate soluble CD8\(^+\) T cell response retention are warranted. Notably, we also found that Pol-specific CD8\(^+\) T cells from some virus controllers mediated antigen-specific virus inhibition. Borthwick et al. recently reported that an HIV conserved immunogen vaccine (prime-boost) strategy induced CD8\(^+\) T cell virus inhibition that correlated with both Gag and Pol CD8\(^+\) T cells (71).

The expression of cytokines has long been associated with soluble antiviral functions. The regulation of these cytokines, however, is poorly understood. We assessed transcription and decay rates for mRNAs in unstimulated and stimulated (p24, p17, and Nef) CD8\(^+\) T cells and found that both mechanisms drive induction of key cytokines, with maximum increases in stability and net transcription occurring at the same time. This induction of gene expression via the cooperation of signaling pathways to bring about increased transcription and enhanced stability to induce multiple cytokines with antiviral activity is an interesting contrast to the usual gene expression buffering seen in eukaryotes (72). There are several mechanisms known to enhance transcription
Temporal expression of antiviral cytokines is quicker and more robust in CD8⁺ T cells with higher RNA stability. (A) Diagram of time course experiments. Cells were labeled with 4sU for 1-h segments after stimulation for 6.5 h with p24 peptide, and then the RNA was separated to measure the net transcription. The levels of total mRNA were predicted using a prestimulation total, net transcription over each hour-long time period, and the prestimulation decay rate. These predictions were then compared to observed total mRNA abundances. (B and C) For unchanged (RANTES) (B) or transcriptionally induced (TNFRSF9) (C) genes, the model (red lines) accurately predicted the observed levels of mRNA abundance (blue lines). (D to F) For IFN-γ (D), MIP-1α (E), and MIP-1β (F), however, the levels of total mRNA observed were much greater than a constant decay rate predicted. (G to K) We calculated optimized mRNA stabilities based on the observed mRNA totals using the following formula: \( \text{DR}_{\text{optimized}} = \frac{(T_i - 1 + N_i - T_{i-1})}{T_i - T_{i-1}} \), where \( T_i \) is the measured total mRNA at time \( i \) and \( N_i \) is the measured net transcription at time \( i \). The optimized stability of mRNA increased in coordination with increases in net transcription, so that mRNAs underwent a "peaked" stability response that correlated with the transcriptional induction. Error bars indicate standard error.
have long untranslated regions (UTRs) and contain AU-rich destabilize it in T cells stimulated with CD3 (60). The RBP Roquin/H9251
cance in the fold change in stability of MIP-1
stimulated cells (Table 3). These observations fit with previous
P in Nef-stimulated cells while we observed signifi-
cences among epitope-driven responses by different CD8
protein required for miRNA processing, resulted in CD8+ T cells that responded faster after anti-CD3 and anti-CD28 stimulation but
result from regulation of the stability of mRNAs encoding HIV-1
resulted in CD8+ T cells (80), recognizing a specific structural element to drive constitutive decay of target messages (81). While the RNA abundances of these RBPs did not change in these studies (data not shown), it is known that posttranslational modifications can affect their mRNA targeting (82, 83). Changes in miRNA regulation may also underlie changes in mRNA stability. In previous reports, elimination of Dicer, a protein required for miRNA processing, resulted in CD8+ T cells that responded faster after anti-CD3 and anti-CD28 stimulation but
were not able to resolve activating responses (84). After stim-
ulation, miR-130/301 (84) and miR-135 (85) are strongly upregu-
lated in CD8+ T cells. Additionally, large-scale differences in miRNA profiles were observed in naive, effector, and memory CD8+ T cells (86). Identifying the important regulatory RBPs and
miRNAs driving the posttranscriptional responses in HIV-1 anti-
gen-stimulated CD8+ T cells would be a key step in fully understand-
ing the regulation of antiviral cytokine responses.

These results bring up an interesting concept of possible differences among epitope-driven responses by different CD8+ T cell subpopulations. While changes in total RNA did occur in CD8+ T cells with p24- and Nef-stimulated inhibition, statistical analyses revealed a possible difference in the regulation of RNA abund-
dances in p24- and Nef-specific cells. We observed that there was a marked statistically significant increase in the net transcription for several miRNAs encoding antiviral cytokines in cells with p24-specific inhibition of virus while changes in Nef-stimulated cells were less dramatic and not significant. Interestingly, comparing p24- and Nef-stimulated cells to autologous p17-stimulated cells, we observed significant changes in the stability of IFN-γ, MIP-1α, and MIP-1αP in Nef-stimulated cells while we observed signifi-
cance in the fold change in stability of MIP-1αP only in p24-
stimulated cells (Table 3). These observations fit with previous
reports that Nef responses are the first to arise in acute infections (87), which may be a reflection of the rapid expression that can be garnered through regulation of RNA stability, allowing a more immediate display of effector function. However, further studies are needed to examine the potential differences in the p24- and
Nef-specific CD8+ T cell responses to determine if regulation by

transcription and RNA stability is dependent on antigen specific-
ity and, if so, whether the stage of memory cell differentiation (88)
of these antigen-specific CD8+ T cells is a factor.

Induction of CD8+ T cells capable of inhibiting HIV-1 replication is important for both development of cure therapies (89) and HIV-1 vaccine strategies. Here, we report on the antigen speci-
cificity, cytokine signature, and regulation of CD8+ T cells that
inhibit virus replication in virus controllers. The finding that RNA stability is involved in the CD8+ T cell response allows possible future identification of other markers of CD8+ T cell effector function using techniques aimed at globally identifying miRNAs that exhibit increased stabilization and other posttranscriptional changes in CD8+ T cells with anti-HIV-1 effector function. The results of this approach can be applied to the design of vaccine immunogens in order to target well-defined HIV-1-specific CD8+ T cells that mediate the stabilization and rapid release of β-chemokines and other antiviral cytokines upon antigen en-
counter to block HIV-1 acquisition.

ACKNOWLEDGMENTS

This work was supported by RO1/R56 NIH grant AI-52779 (G.D.T.), an NIH F31 fellowship (1F31AI106519-01) (T.L.P.), and Center for AIDS Research (P30 AI 64518) and Duke Interdisciplinary Research Training Program in AIDS (NIH IRTPA T32) grant ST32AI007392 (J.B.). Work by J.B. was also supported by grants from the National Cancer Institute (grant number R01 CA157268 to J.D.K.), and the National Science Foundation (0842621 to J.D.K.).

We thank Kent Weinhold, Director of the Duke CFAR, and Coleen Cunningham and John Bartlett, Directors of the Duke CFAR Clinical Core, and the patients, physicians, and staff of the Duke Adult Infectious Diseases Clinic (Sunita Patil, Gary Cox, Nathan Thielman, Cameron Wolfe, Elizabeth Livingston, Brianna Norton, Kristen Dicks, Mehri McKellar, Vivian Chu, Jason Stout, and Ann Mosher) for virus controller patient recruitment. We thank John Kappes, Christina Ochsenbauer, and the UAB CFAR Virology Core for HIV-1 infectious molecule clones and Cavin Ward-Caviness for helpful discussions.

REFERENCES


Downloaded from http://jvi.asm.org on October 16, 2017 by guest


